Tecentriq atezolizumab: Additional Phase III data

Additional data from the ITT population comprising the first 850 patients with locally advanced or metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy enrolled in the open-label, international Phase III OAK trial showed that 1,200 mg IV Tecentriq given every 3 weeks led to a median OS of 13.8 months vs. 9.6 months for IV docetaxel (p=0.0003). In a subgroup of 463 patients with PD-L1 expression on >=1% of tumor or tumor-infiltrating immune cells, Tecentriq led to a median OS of 15.7 months vs. 10.3 months for docetaxel (p=0.0102). In a subgroup of 379 patients with <=1% PD-L1 expression, Tecentriq led to a median OS of 12.9 months vs. 8.9 months for docetaxel (p=0.0205). In patients with non-squamous disease (n=628), Tecentriq led to a median OS of 15.6 months vs. 11.2 months for docetaxel. In patients with squamous disease (n=222), Tecentriq led to a median OS of 8.9 months vs. 7.7 months for docetaxel. The primary analysis consisted of the first 850 patients enrolled, while the secondary endpoints included all 1,225 patients enrolled. Data were presented at the European Society for Medical Oncology meeting in Copenhagen. Roche previously reported that Tecentriq met the co-primary endpoints of improving OS in the ITT population and in a subgroup of patients with PD-L1 expression (see BioCentury, Sept. 5). ...